Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

In the wake of US funding cuts for global aid, numerous donor-funded health facilities in South Africa have shut down and ...

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...